Please ensure Javascript is enabled for purposes of website accessibility

Sanofi Acquiring Principia Biopharma for $3.7 Billion

By Eric Volkman - Updated Aug 17, 2020 at 4:58PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

This isn't the pharmaceutical giant's only recent ride at the acquisition rodeo.

Sanofi (SNY -3.94%) announced a fresh acquisition on Monday morning. The sprawling pharmaceutical company said it has agreed to purchase biotech Principia Biopharma (PRNB) for $100 per share in an all-cash transaction. This equates to a total outlay of roughly $3.68 billion.

Principia specializes in the development of drugs to treat autoimmune disorders, a very active product category in the pharmaceutical industry just now. The company currently has three pipeline treatments; two of these are currently undergoing phase 3 clinical testing. One, Rilzabrutinib, targets pemphigus, a rare disease that can result in the development of blisters on the skin and on mucous membranes.

Numerous pills and vials atop $100 bills.

Image source: Getty Images.

Sanofi and Principia are already business partners. In 2017, Sanofi was granted an exclusive global license to develop one of its pipeline drugs, BTK inhibitor '168, for the treatment of certain lesions arising from multiple sclerosis. Like Rilzabrutinib, BTK inhibitor '168 is currently in a phase 3 trial.

"This acquisition advances our ongoing R&D transformation to accelerate development of the most promising medicines that will address significant patient needs," according to Sanofi CEO Paul Hudson. 

This is Sanofi's second major acquisition with Hudson at the helm. Last December, the company struck a deal to acquire clinical-stage immuno-oncology specialist Synthorx in a transaction valued at $2.5 billion.

The Sanofi/Principia deal, which the acquirer said will be funded from cash on hand, is subject to approval from the relevant regulatory bodies. Sanofi expects it to close in the fourth quarter of this year.

Investors seem to approve of the new acquisition. Sanofi closed just over 2% higher on Monday, well outpacing the gains of the broader stock market.


Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Sanofi Stock Quote
$43.42 (-3.94%) $-1.78
Principia Biopharma Inc. Stock Quote
Principia Biopharma Inc.

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/12/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.